RCKT Rocket Pharmaceuticals Inc.

14.71
-0.01  -0%
Previous Close 14.72
Open 14.99
Price To Book 2.64
Market Cap 810,097,264
Shares 55,071,194
Volume 391,012
Short Ratio
Av. Daily Volume 443,721
Stock charts supplied by TradingView

NewsSee all news

  1. Rocket Pharmaceuticals Provides Business Update in Light of COVID-19 Pandemic

    —Continue to Believe We Will Achieve 2020 Milestones— — Balance Sheet is Strong; Company Capital Will Be Sufficient into 2022 — Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company

  2. Rocket Pharmaceuticals Announces Participation at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that management will

  3. Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease

    – Results Demonstrate AAV9 Gene Therapy of LAMP2B Reverses Clinical Manifestations of Danon Disease in Mouse Study – Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an

  4. Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia

    MENLO PARK, Calif. and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV) and Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced today that they have entered into a research collaboration to

  5. Rocket Pharmaceuticals Reports Full Year 2019 Financial Results and Operational Highlights

    —Construction of R&D and cGMP Manufacturing Facility Underway in New Jersey— —Preliminary Clinical Data of RP-L102 in FA and RP-L201 in LAD-I Support Potential of Lentiviral Pipeline and "Process B"

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 top-line data released January 3, 2017. Primary endpoint not met.
Trabodenoson
Primary open-angle glaucoma (POAG)
Phase 2 trial failed - noted July 7, 2017.
Trabodenoson and latanoprost
Glaucoma
Phase 1 data update 2H 2020.
RP-L201
Leukocyte Adhesion Deficiency-I (LAD-I)
Phase 1 data due 2H 2020.
RP-A501
Danon disease
Phase 1 trial has commenced with data due 2H 2020.
RP-L301
Pyruvate Kinase Deficiency (PKD)
Phase 2 initial data due 2H 2020.
RP-L102
Fanconi Anemia (FA)

Latest News

  1. Rocket Pharmaceuticals Provides Business Update in Light of COVID-19 Pandemic

    —Continue to Believe We Will Achieve 2020 Milestones— — Balance Sheet is Strong; Company Capital Will Be Sufficient into 2022 — Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company

  2. Rocket Pharmaceuticals Announces Participation at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that management will

  3. Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease

    – Results Demonstrate AAV9 Gene Therapy of LAMP2B Reverses Clinical Manifestations of Danon Disease in Mouse Study – Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an

  4. Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia

    MENLO PARK, Calif. and NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV) and Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced today that they have entered into a research collaboration to

  5. Rocket Pharmaceuticals Reports Full Year 2019 Financial Results and Operational Highlights

    —Construction of R&D and cGMP Manufacturing Facility Underway in New Jersey— —Preliminary Clinical Data of RP-L102 in FA and RP-L201 in LAD-I Support Potential of Lentiviral Pipeline and "Process B"

  6. Rocket Pharmaceuticals Announces Publication of Manuscript Evaluating Mosaicism in Fanconi Anemia

    - Publication Affirms Rocket's Approach to Treating Fanconi Anemia - Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies

  7. Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces participation at the

  8. Rocket Pharmaceuticals Announces Private Exchange Transactions Regarding Outstanding Convertible Senior Notes due 2021

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that on February 10,

  9. Rocket Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Awareness

    —Educational Event at Carnegie Hall Featuring Patient Discussions and Opportunities for Patients and Families to Engage with Physicians and Researchers in the NY Healthcare Community— —Empire State Building to

  10. Rocket Pharmaceuticals Announces Participation at the 38th Annual J.P. Morgan Healthcare Conference

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Gaurav Shah, M.D.,

  11. Rocket Pharmaceuticals Receives the European Medicines Agency PRIME Eligibility for RP-L102 Gene Therapy for Fanconi Anemia

    - Milestone Gives Fanconi Anemia Program All Accelerated Regulatory Tools in U.S. and EU, Including FDA Regenerative Medicine Advanced Therapy, Fast Track and Orphan Designations - Rocket Pharmaceuticals, Inc.

  12. Rocket Pharmaceuticals Announces Closing of Public Offering

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the closing of its

  13. Rocket Pharmaceuticals Prices Public Offering of Common Stock

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the pricing of an

  14. Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that it has commenced

  15. Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I

    - Initial Data Demonstrated Robust CD18 Expression and Resolution of Disease-Mediated Lesions in Months After Gene Therapy Treatment - Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company

  16. Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 "Process B" for Fanconi Anemia at 61st American Society of Hematology Annual Meeting

    —US Phase 1 Trial Establishes Feasibility of Commercial "Process B" Vector/Cell Manufacturing in FA— —Preliminary Data Demonstrate Evidence of Early Engraftment Without Conditioning Four to Six Months after

  17. Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 "Process B" for Fanconi Anemia

    —Preliminary Phase 2 Data Anticipated in 2020— Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood

  18. Rocket Pharmaceuticals to Host Breakout Session at 61st American Society of Hematology Annual Meeting

    —Event to Highlight Preliminary Data from the Phase 1 Trial of RP-L102 "Process B" for Fanconi Anemia and from the Phase 1 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I— Rocket Pharmaceuticals, Inc.

  19. Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces participation at the

  20. Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

    –First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 "Process A" for Fanconi Anemia– –Four Gene Therapies Now in the Clinic– –Initial Data from FA "Process B"

  21. Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 "Process B" for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting

    —Rocket Management to Hold a Breakout Session with KOLs to Discuss Data Following Presentation at 8:30 p.m. EST on December 8th— Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based

  22. Rocket Pharmaceuticals Announces Participation at the Barclays Gene Editing & Gene Therapy Summit

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket is

  23. Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 "Process A" for Fanconi Anemia

    – Early Signs of Hematologic Correction in Initial Patients Who Received Adequate Drug Product– – First Four "Process A" Patients Demonstrate Long-Term Evidence of Increasing and Durable Engraftment Resembling FA

  24. Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress

    —New Long-Term "Process A" Data from the Phase 1/2 EUROFANCOLEN Trial of RP-L102 to be Featured in Oral Session— Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform gene therapy

  25. Rocket Pharmaceuticals Announces Participation at the Chardan 3rd Annual Genetic Medicines Conference

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket is

  26. Rocket Pharmaceuticals Announces IMPD Clearance of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency

     –Rocket's Largest Lentiviral Pipeline Opportunity with an Estimated Prevalence of 3,000 to 8,000 Patients in the U.S. and EU– –Phase 1 Clinical Trial to Commence in the Fourth Quarter– Rocket Pharmaceuticals, Inc.

  27. Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine

    —First Demonstration of Successful Engraftment of Gene Corrected Hematopoietic Stem Cells Without the Use of Conditioning— Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform

  28. Rocket Pharmaceuticals Announces First Patient Treated in Phase 1/2 Registrational Trial of RP-L201 for LAD-I

    - Preliminary Phase 1 Data Expected by the End of 2019 - Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that the first

  29. Rocket Pharmaceuticals Announces Registration-Enabling Phase 2 Plans for RP-L102 Gene Therapy for Fanconi Anemia Following a Supportive End-of-Phase 1 FDA Meeting

    — U.S. Phase 2 Trial to Use MMC-Resistance as Primary Endpoint, Supported by Additional Blood Count, Genetic and Phenotypic Assessments — — Global Product Licensure Strategy Aligned Across U.S. and E.U. — Rocket

  30. Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces participation at the following upcoming conferences: Citi's 14ᵗʰ Annual

  31. Rocket Pharmaceuticals Announces Clearance from the Spanish Agency for Medicines and Health Products for the Phase 2 Registration-enabling FANCOLEN-II Study of RP-L102 for Fanconi Anemia

    —Phase 2 Trial to Commence Patient Enrollment in Europe— — Rocket-sponsored Registration-enabling Study Utilizing Optimized Process B— Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) ("Rocket"), a leading U.S.-based